Statement: Cohort 1 of the primary trial had a much higher mortality rate than cohort 2.
Primary_evidence: Adverse Events 1:   Total: 4/6 (66.67%)   Anemia  0/6 (0.00%)   Takotsubo cardiomyopathy  1/6 (16.67%)   Pericardial effusion  0/6 (0.00%)   Vertigo  1/6 (16.67%)   Retinal vein occlusion  0/6 (0.00%)   Gastroenteritis  1/6 (16.67%)   Vomiting  1/6 (16.67%)   Diarrhea  0/6 (0.00%)   Death  2/6 (33.33%)   Bile duct dilatation  0/6 (0.00%)   Hepatic hemorrhage  0/6 (0.00%) Adverse Events 2:   Total: 25/52 (48.08%)   Anemia  1/52 (1.92%)   Takotsubo cardiomyopathy  0/52 (0.00%)   Pericardial effusion  2/52 (3.85%)   Vertigo  0/52 (0.00%)   Retinal vein occlusion  1/52 (1.92%)   Gastroenteritis  0/52 (0.00%)   Vomiting  0/52 (0.00%)   Diarrhea  1/52 (1.92%)   Death  9/52 (17.31%)   Bile duct dilatation  1/52 (1.92%)   Hepatic hemorrhage  1/52 (1.92%)